Chembio Diagnostics
In Brief This Week: PerkinElmer, Chembio, Becton Dickinson, Fulgent Genetics, and More
News items for the in vitro diagnostic industry for the week of Sept. 20, 2021.
Chembio Distributing InBios SARS-CoV-2 Rapid Antigen Test
The InBios SCoV-2 Ag Detect rapid test is authorized for use in laboratories with a CLIA-waiver and provides results in 20 minutes without an instrument.
Chembio Diagnostics Q2 Revenues Rise 27 Percent; Firm Conducts Going Concern Evaluation
The firm said its revenues did not meet its expectations and were a principal cause of limited cash and cash-equivalents position at the end of the quarter.
Facing SEC Investigation, Chembio Diagnostics Reports 25 Percent Lift in Preliminary Q2 Revenues
The point-of-care diagnostics company also announced a $60M at-the-market sales agreement for shares of its common stock with the investment bank Craig-Hallum.
Chembio Diagnostics Q1 Revenues Climb 26 Percent on Government Grant Income
The firm said that in Q1 its product revenues fell 30 percent year over year to $4.0 million, but government grant income contributed $3.4 million to its revenues.